Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis

Zhang, Jianeng; Zhang, Huanhuan; Zhou, Wenjing; Jiang, Meiyan; Lin, Xianhua

doi:10.3389/fendo.2025.1520362

SYSTEMATIC REVIEW article

Front. Endocrinol.

Sec. Reproduction

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1520362

Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis

Provisionally accepted

Jianeng Zhang

Huanhuan Zhang ^*

Wenjing Zhou

Meiyan Jiang

Xianhua Lin

Hangzhou Women’s Hospital, Hangzhou, China

The final, formatted version of the article will be published soon.

Objective: There has been substantial research conducted recently on the effect of myo-inositol (MI) on human reproduction. However, it still remains ambiguous about the therapeutic efficacy of MI in infertile women undergoing in vitro fertilization embryo transfer (IVF-ET). This systematic review and meta-analysis was carried out to investigate the efficacy of MI on IVF outcomes. Methods: Literatures were searched in the PubMed, Web of Science, Cochrane Library, ScienceDirect and Wanfang databases. The methodological quality was assessed using the Cochrane Risk of Bias tool. Data were pooled using a random-or fixed-effects model according to study heterogeneity. The results are expressed as odds ratio (OR) or mean difference (MD) with 95% confidence intervals (CIs). Heterogeneity was measured by the I 2 statistic. The protocol was prospectively registered with PROSPERO (CRD42024582149).Results: Eleven eligible studies with 981 participants reported the IVF outcomes of the MI group versus the control group. The synthesis results showed that the metaphase II (MII) oocyte rate was higher in the MI group than in the control group (OR 1.55, 95% CI 1.04-2.31, P=0.03)). For polycystic ovary syndrome (PCOS) women, as well as non-obese PCOS women, a statistically significant improvement in MII oocyte rate were assumed after taking MI (OR 1.97, 95% CI 1.20-3.25, P＜0.01; OR 1.92, 95% CI 1.09-3.37, P=0.02) while there is no statistically significant advancement showed in the poor ovary responder (POR) women (OR 0.97, P=0.95 ). The fertilization rate was higher in the MI group than in the control group (OR 1.62, P＜0.01), for PCOS, non-obese PCOS and POR women (OR 1.59, 95% CI 1.16-2.18, P0.01; OR 1.87, 95% CI 1.52-2.31, P0.01; OR 2.42, 95% CI 1.48-3.95, P＜0.01).Our results suggest that MI supplementation improves the MII oocyte rate and the fertilization rate. More high-grade evidence from prospective randomized studies is warranted.

Keywords: myo-inositol, In vitro fertilization embryo transfer, Polycystic Ovary Syndrome, Poor ovary responder, outcomes

Received: 31 Oct 2024; Accepted: 26 Feb 2025.

Copyright: © 2025 Zhang, Zhang, Zhou, Jiang and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Huanhuan Zhang, Hangzhou Women’s Hospital, Hangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.